Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): A prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets

Annals of the Rheumatic Diseases

Volumn 71, Issue 3, 2012, Pages 415-423

  De Launay, Daphne ^a   Van De Sande, Marleen G H ^a   De Hair, Maria J H ^a   Grabiec, Aleksander M ^a   Van De Sande, Gijs P M ^a   Lehmann, K Aad ^a   Wijbrandts, Carla A ^a   Van Baarsen, Lisa G M ^a   Gerlag, Danielle M ^a   Tak, Paul P ^a   Reedquist, Kris A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HERMES ANTIGEN; MESSENGER RNA; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIGITAL IMAGING; DISEASE CLASSIFICATION; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JOINT BIOPSY; LOW DRUG DOSE; MALE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REACTIVE ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHRITIS; SPONDYLOARTHROPATHY; UNDIFFERENTIATED ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROGNOSIS; PROSPECTIVE STUDIES; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; YOUNG ADULT;

EID: 84857238808     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.143529     Document Type: Article

References (47)

1. Thalhamer T, McGrath MA, Harnett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008;47:409-14.
2. Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008;67:909-16. (Pubitemid 351956650)
3. Han Z, Boyle DL, Aupperle KR, et al. Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999;291:124-30. (Pubitemid 29451581)
4. Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501-12.
5. Korb A, Tohidast-Akrad M, Cetin E, et al. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum 2006;54:2745-56. (Pubitemid 44497753)
6. Nishikawa M, Myoui A, Tomita T, et al. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48:2670-81. (Pubitemid 37129445)
7. Westra J, Limburg PC, de Boer P, et al. Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 2004;63:1453-9. (Pubitemid 39433951)
8. Mbalaviele G, Anderson G, Jones A, et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther 2006;317:1044-53. (Pubitemid 43764107)
9. Kunisch E, Gandesiri M, Fuhrmann R, et al. Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Ann Rheum Dis 2007;66:1043-51. (Pubitemid 47122317)
10. Thiel MJ, Schaefer CJ, Lesch ME, et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthritis Rheum 2007;56:3347-57. (Pubitemid 47585429)
11. Rockel JS, Bernier SM, Leask A. Egr-1 inhibits the expression of extracellular matrix genes in chondrocytes by TNFalpha-induced MEK/ERK signalling. Arthritis Res Ther 2009;11:R8.
12. Han Z, Boyle DL, Chang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81. (Pubitemid 32634924)
13. Hammaker DR, Boyle DL, Chabaud-Riou M, et al. Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. J Immunol 2004;172:1612-18. (Pubitemid 38116808)
14. Medicherla S, Ma JY, Mangadu R, et al. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 2006;318:132-41.
15. Zwerina J, Hayer S, Redlich K, et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006;54:463-72. (Pubitemid 43228620)
16. Hill RJ, Dabbagh K, Phippard D, et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther 2008;327:610-19.
17. Fusello AM, Mandik-Nayak L, Shih F, et al. The MAPK scaffold kinase suppressor of Ras is involved in ERK activation by stress and proinflammatory cytokines and induction of arthritis. J Immunol 2006;177:6152-8. (Pubitemid 44628832)
18. Han Z, Chang L, Yamanishi Y, et al. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 2002;46:818-23. (Pubitemid 34214265)
19. Sweeney SE, Firestein GS. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis 2006;65 Suppl 3:iii83-8. (Pubitemid 44629110)
20. Tas SW, Remans PH, Reedquist KA, et al. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr Pharm Des 2005;11:581-611. (Pubitemid 40277870)
21. Görtz B, Hayer S, Tuerck B, et al. Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. Arthritis Res Ther 2005;7:R1140-7.
22. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:335-44.
23. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60:1232-41.
24. Fukushima A, Boyle DL, Corr M, et al. Kinetic analysis of synovial signalling and gene expression in animal models of arthritis. Ann Rheum Dis 2010;69:918-23.
25. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
26. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
27. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
28. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
29. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
30. van der Heijde D, Dankert T, Nieman F, et al. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:941-7. (Pubitemid 29505074)
31. Gerlag DM, Tak PP. How to perform and analyse synovial biopsies. Best Pract Res Clin Rheumatol 2009;23:221-32.
32. Gerlag D, Tak PP. Synovial biopsy. Best Pract Res Clin Rheumatol 2005;19:387-400.
33. Smeets TJ, Barg EC, Kraan MC, et al. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 2003;62:635-8. (Pubitemid 36760560)
34. Haringman JJ, Vinkenoog M, Gerlag DM, et al. Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther 2005;7:R862-7.
35. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9. (Pubitemid 37280601)
36. Berglin E, Johansson T, Sundin U, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006;65:453-8.
37. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:317-20.
38. Lories RJ, Derese I, Luyten FP, et al. Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin Exp Rheumatol 2008;26:96-102. (Pubitemid 351385261)
39. Clark AR, Dean JL, Saklatvala J. The p38 MAPK pathway mediates both antiinflammatory and proinflammatory processes: comment on the article by Damjanov and the editorial by Genovese. Arthritis Rheum 2009;60:3513-14.
40. van der Linden MP, Knevel R, Huizinga TW, et al. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 2011;63:37-42.
41. Guma M, Kashiwakura J, Crain B, et al. JNK1 controls mast cell degranulation and IL-1{beta} production in inflammatory arthritis. Proc Natl Acad Sci USA 2010;107:22122-7.
42. Naor D, Nedvetzki S. CD44 in rheumatoid arthritis. Arthritis Res Ther 2003;5:105-15.
43. Wibulswas A, Croft D, Bacarese-Hamilton I, et al. The CD44v7/8 epitope as a target to restrain proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Am J Pathol 2000;157:2037-44.
44. Wibulswas A, Croft D, Pitsillides AA, et al. Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. Arthritis Rheum 2002;46:2059-64.
45. Tolboom TC, Huidekoper AL, Kramer IM, et al. Correlation between expression of CD44 splice variant v8-v9 and invasiveness of fibroblast-like synoviocytes in an in vitro system. Clin Exp Rheumatol 2004;22:158-64. (Pubitemid 38444805)
46. Neidhart M, Gay RE, Gay S. Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2000;43:1719-28.
47. Mikecz K, Dennis K, Shi M, et al. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthritis Rheum 1999;42:659-68. (Pubitemid 29171985)